You know the drill by now. You're sitting in the purgatory of the service center waiting room. Precisely 63 minutes into your wait, the service adviser walks out with a clipboard and calls your name — ...

Even as OpenAI works to harden its Atlas AI browser against cyberattacks, the company admits that prompt injections, a type of attack that manipulates AI agents to follow malicious instructions often ...

GLP-1 medications have rapidly become some of the most influential treatments for Type 2 diabetes and weight loss. As more people look into these prescriptions, there is growing curiosity about how ...

A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be less likely to develop epilepsy than those taking DPP-4 inhibitors.

Many other drugmakers are attempting to break this duopoly, but this may not happen anytime soon. GLP-1 medicines are all the rage in the pharmaceutical industry these days. Recent breakthroughs in ...

This article originally appeared on PolitiFact. If you watch TV and don't mute ads, you've probably heard of a few biologics. They're drugs such as Humira for arthritis and Trulicity for Type 2 ...

President Donald Trump on Thursday announced deals with pharmaceutical giants Novo Nordisk and Eli Lilly that would cut the cost of the lowest doses of their in-demand weight-loss drugs, lowering the ...

Sherri Gordon, CLC is a certified professional life coach, author, and journalist covering health and wellness, social issues, parenting, and mental health. She also has a certificate of completion ...

The body’s defenses may be mildly lowered for about 1 to 4 weeks after a single steroid shot into a joint or near your spine. In some people, particularly with higher doses, this effect may last up to ...

The global GLP-1 market has been in the spotlight for the past couple of years as big pharma players realize its multi-billion-dollar potential and the untapped nature. It is currently dominated by ...

Like many men his age, William Stern was tired. At 45, the husband, father of three, and founder of Cardiff, a small-business lender, said he felt grateful but “run down” by his very full life.

The duel of the GLP-1 data sets continues this week, with Novo issuing the latest salvo of updates on its oral obesity candidate and an Ozempic head-to-head trial win against another stalwart diabetes ...